

In the claims:

Please amend claims 23, 25, 27, 29, 33-36, 39, 40, 43, 44, 47, 48, 60-67, 72-74, 77, 78, 81, 82, 85 and 86 as follows.

²
D² ~~3.~~_{23.} (Once Amended) The polypeptide of claim ~~22.~~^{2.}, wherein the amino acid sequence is fused to a heterologous polypeptide.

³
D³ ~~5.~~_{25.} (Once Amended) The polypeptide of claim ~~24.~~^{4.}, wherein the amino acid sequence is fused to a heterologous polypeptide.

⁴
D⁴ ~~7.~~_{27.} (Once Amended) The polypeptide of claim ~~26.~~^{6.}, wherein the amino acid sequence is fused to a heterologous polypeptide.

⁵
D⁵ ~~9.~~_{29.} (Once Amended) The polypeptide of claim ~~28.~~^{8.}, wherein the amino acid sequence is fused to a heterologous polypeptide.

⁶
D⁶ ~~10.~~_{30.} (Once Amended) The polypeptide of claim ~~22.~~^{2.}, wherein the amino acid sequence is fused to a heterologous polypeptide.

⁷
D⁷ ~~11.~~_{31.} (Twice Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

(a) amino acids 1 to 381 of SEQ ID NO:2;

D⁷ cont'd
(b) amino acids 2 to 381 of SEQ ID NO:2;

(c) amino acids 25 to 381 of SEQ ID NO:2; and

(d) a polypeptide fragment of SEQ ID NO:2,

wherein said polypeptide or polypeptide fragment stimulates cellular proliferation.

D⁸
12. ~~35~~ (Once Amended) The polypeptide of claim ~~34~~¹¹, wherein said second amino acid sequence is (a).

13. ~~38~~ (Once Amended) The polypeptide of claim ~~35~~¹², wherein the amino acid sequence is fused to a heterologous polypeptide.

D⁹
14. ~~39~~ (Once Amended) The polypeptide of claim ~~34~~¹¹, wherein said second amino acid sequence is (b).

15. ~~40~~ (Once Amended) The polypeptide of claim ~~39~~¹⁴, wherein the amino acid sequence is fused to a heterologous polypeptide.

D¹⁰
16. ~~43~~ (Once Amended) The polypeptide of claim ~~34~~¹¹, wherein said second amino acid sequence is (c).

17. ~~44~~ (Once Amended) The polypeptide of claim ~~43~~¹⁶, wherein the amino acid sequence is fused to a heterologous polypeptide.

¹¹
18. ~~47.~~ (Once Amended) The polypeptide of claim ~~34~~, wherein said second amino acid sequence is (d).

¹¹
19. ~~48.~~ (Once Amended) The polypeptide of claim ~~47~~, wherein the amino acid sequence is fused to a heterologous polypeptide.

²⁰
21. ~~60.~~ (Once Amended) The polypeptide of claim ~~59~~, wherein said amino acid sequence is (a).

²¹
22. ~~61.~~ (Once Amended) The polypeptide of claim ~~60~~, wherein the amino acid sequence is fused to a heterologous polypeptide.

²⁰
23. ~~62.~~ (Once Amended) The polypeptide of claim ~~59~~, wherein said amino acid sequence is (b).

²³
24. ~~63.~~ (Once Amended) The polypeptide of claim ~~62~~, wherein the amino acid sequence is fused to a heterologous polypeptide.

²⁰
25. ~~64.~~ (Once Amended) The polypeptide of claim ~~59~~, wherein said amino acid sequence is (c).

²⁵
26. ~~65.~~ (Once Amended) The polypeptide of claim ~~64~~, wherein the amino acid sequence is fused to a heterologous polypeptide.

27.
~~56.~~

20.
~~59.~~

(Once Amended) The polypeptide of claim ~~59~~, wherein said amino acid

sequence is (d).

28.
~~67.~~

27.
~~68.~~

(Once Amended) The polypeptide of claim ~~68~~, wherein the amino acid

sequence is fused to a heterologous polypeptide.

29.
~~72.~~

(Twice Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904;

(b) the amino acid sequence of the full-length polypeptide, lacking the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit Number 75904;

(c) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904; and

(d) a polypeptide fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904;

wherein said polypeptide or polypeptide fragment stimulates cellular proliferation.

30.
~~73.~~

29.
~~72.~~

(Once Amended) The polypeptide of claim ~~72~~, wherein said second amino acid sequence is (a).

D¹⁴

~~31.~~
~~74.~~

(Once Amended) The polypeptide of claim ~~73~~³⁰, wherein the amino acid sequence is fused to a heterologous polypeptide.

~~32.~~
~~77.~~

(Once Amended) The polypeptide of claim ~~72~~²⁹, wherein said second amino acid sequence is (b).

D¹⁵

~~33.~~
~~78.~~

(Once Amended) The polypeptide of claim ~~77~~³², wherein the amino acid sequence is fused to a heterologous polypeptide.

~~34.~~
~~81.~~

(Once Amended) The polypeptide of claim ~~72~~²⁹, wherein said second amino acid sequence is (c).

D¹⁶

~~35.~~
~~82.~~

(Once Amended) The polypeptide of claim ~~81~~³⁴, wherein the amino acid sequence is fused to a heterologous polypeptide.

~~36.~~
~~83.~~

(Once Amended) The polypeptide of claim ~~72~~²⁹, wherein said second amino acid sequence is (d).

D¹⁷

~~37.~~
~~84.~~

(Once Amended) The polypeptide of claim ~~83~~³⁶, wherein the amino acid sequence is fused to a heterologous polypeptide.